Clinical Trial Update: Vadastuximab Talirine (SGN-CD33A; 33A) Combined With Azacitidine or Decitabine in Older Patients With Newly Diagnosed Acute Myeloid Leukemia [Phase 3]

View source ↗

Summary

Phase 3 trial update for vadastuximab talirine combined with azacitidine or decitabine in older patients with newly diagnosed acute myeloid leukemia; study term…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Myeloid Leukemia

Drugs mentioned

• AZACITIDINE (AZACITIDINE)
• Decitabine (Decitabine)
• Vadastuximab Talirine (Vadastuximab Talirine)

Snippet

Sponsor: Seagen Inc. | Conditions: Acute Myeloid Leukemia | Phase 3 | Status: TERMINATED | Results posted: 2018-12-12